Items Tagged ‘Management and Prevention of Nausea and Vomiting Supportive Care’

July 9th, 2012

Arrhythmia Risk Leads to Label Change for Zofran

By

Interim data from a recent clinical trial has indicated that a 32 mg single dose of Zofran® (ondansetron) may affect the electrical activity of the heart and could predispose patients to develop an abnormal heart rhythm. The U.S. Food and Drug Administration (FDA) has released a drug safety communication and GlaxoSmithKline, the manufacturer, has responded […]

View full entry

Tags: Management and Prevention of Nausea and Vomiting Supportive Care, News, Supportive Care